These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 18216038

  • 21. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM, Zhang SY, Song T, Xu WH, Lin XN, Shu J, Liu L.
    Chin Med J (Engl); 2008 Dec 05; 121(23):2434-9. PubMed ID: 19102964
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study.
    D'Angelo A, Davies R, Salah E, Nix BA, Amso NN.
    Fertil Steril; 2004 Feb 05; 81(2):332-6. PubMed ID: 14967369
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation.
    Artini PG, Monti M, Matteucci C, Valentino V, Cristello F, Genazzani AR.
    Gynecol Endocrinol; 2006 Aug 05; 22(8):465-70. PubMed ID: 17012110
    [Abstract] [Full Text] [Related]

  • 26. Elevated levels of CRP in ovarian hyperstimulation syndrome: an unrecognised potential hazard?
    Levin I, Gamzu R, Pauzner D, Rogowski O, Shapira I, Maslovitz S, Almog B.
    BJOG; 2005 Jul 05; 112(7):952-5. PubMed ID: 15957998
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Increased erythrocyte aggregation in ovarian hyperstimulation syndrome: a possible contributing factor in the pathophysiology of this disease.
    Levin I, Gamzu R, Hasson Y, Lessing JB, Amit A, Shapira I, Berliner S, Almog B.
    Hum Reprod; 2004 May 05; 19(5):1076-80. PubMed ID: 15044400
    [Abstract] [Full Text] [Related]

  • 29. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A.
    Hum Reprod Update; 2008 May 05; 14(4):321-33. PubMed ID: 18385260
    [Abstract] [Full Text] [Related]

  • 30. Interleukin-18 is high in the serum of IVF pregnancies with ovarian hyperstimulation syndrome.
    Gutman G, Soussan-Gutman L, Malcov M, Lessing JB, Amit A, Azem F.
    Am J Reprod Immunol; 2004 May 05; 51(5):381-4. PubMed ID: 15212675
    [Abstract] [Full Text] [Related]

  • 31. Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF.
    Artini PG, Ruggiero M, Parisen Toldin MR, Monteleone P, Monti M, Cela V, Genazzani AR.
    Hum Fertil (Camb); 2009 Mar 05; 12(1):40-4. PubMed ID: 19330612
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome.
    Aboulghar MA, Mansour RT, Serour GI, El Helw BA, Shaarawy M.
    Eur J Obstet Gynecol Reprod Biol; 1999 Nov 05; 87(1):81-5. PubMed ID: 10579621
    [Abstract] [Full Text] [Related]

  • 34. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome.
    Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, Bekir J, Campbell S, Conway G, Jacobs H.
    Fertil Steril; 1999 Feb 05; 71(2):287-93. PubMed ID: 9988400
    [Abstract] [Full Text] [Related]

  • 35. Coasting acts through downregulation of VEGF gene expression and protein secretion.
    García-Velasco JA, Zúñiga A, Pacheco A, Gómez R, Simón C, Remohí J, Pellicer A.
    Hum Reprod; 2004 Jul 05; 19(7):1530-8. PubMed ID: 15155606
    [Abstract] [Full Text] [Related]

  • 36. Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome.
    Abramov Y, Schenker JG, Lewin A, Kafka I, Jaffe H, Barak V.
    Fertil Steril; 2001 Jul 05; 76(1):51-7. PubMed ID: 11438319
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS, Joo BS, Moon SE, Lee SK, Kim KS, Koo JS.
    Fertil Steril; 2008 Dec 05; 90(6):2172-8. PubMed ID: 18439601
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.